Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will be releasing its earnings data after the market closes on Tuesday, October 31st. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.15) per share for the quarter.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The company had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.01 earnings per share. On average, analysts expect Vanda Pharmaceuticals to post $-0.42 EPS for the current fiscal year and $-0.1 EPS for the next fiscal year.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 15.70 on Tuesday. The stock’s market capitalization is $704.27 million. Vanda Pharmaceuticals Inc. has a 12 month low of $12.70 and a 12 month high of $18.99. The stock has a 50 day moving average price of $17.33 and a 200 day moving average price of $15.76.

ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Set to Announce Earnings on Tuesday” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/24/vanda-pharmaceuticals-inc-vnda-set-to-announce-earnings-on-tuesday.html.

A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research note on Thursday, September 14th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Finally, HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $21.29.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.